1: You S, Liu Y, Arp Z, Zhao Y, Chaney EJ, Marjanovic M, Boppart SA.
Intracellular imaging of docosanol in living cells by coherent anti-Stokes Raman
scattering microscopy. J Biomed Opt. 2017 Jul 1;22(7):70502. doi:
10.1117/1.JBO.22.7.070502. PubMed PMID: 28742922.
<br>
2: [Docosanol (Erazaban), dermal use]. J Pharm Belg. 2011 Jun;(2):53-4. French.
PubMed PMID: 21823443.
<br>
3: Treister NS, Woo SB. Topical n-docosanol for management of recurrent herpes
labialis. Expert Opin Pharmacother. 2010 Apr;11(5):853-60. doi:
10.1517/14656561003691847. Review. PubMed PMID: 20210688.
<br>
4: Docosanol: new drug. Herpes labialis: barely more effective than an excipient.
Prescrire Int. 2009 Jun;18(101):106-7. PubMed PMID: 19637417.
<br>
5: Yue X, Dobner B, Iimura K, Kato T, Möhwald H, Brezesinski G. Weak first-order
tilting transition in monolayers of mono- and bipolar docosanol derivatives. J
Phys Chem B. 2006 Nov 9;110(44):22237-44. PubMed PMID: 17078664.
<br>
6: Leung DT, Sacks SL. Docosanol: a topical antiviral for herpes labialis. Expert
Opin Pharmacother. 2004 Dec;5(12):2567-71. Review. PubMed PMID: 15571473.
<br>
7: Sacks SL. Efficacy of docosanol. J Am Acad Dermatol. 2003 Sep;49(3):558-9.
PubMed PMID: 12963936.
<br>
8: Marcelletti JF. Synergistic inhibition of herpesvirus replication by docosanol
and antiviral nucleoside analogs. Antiviral Res. 2002 Nov;56(2):153-66. PubMed
PMID: 12367721.
<br>
9: Spruance SL. N-docosanol (Abreva) for herpes labialis: problems and questions.
J Am Acad Dermatol. 2002 Sep;47(3):457-8. PubMed PMID: 12196766.
<br>
10: McKeough MB, Spruance SL. Comparison of new topical treatments for herpes
labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream
against experimental cutaneous herpes simplex virus type 1 infection. Arch
Dermatol. 2001 Sep;137(9):1153-8. PubMed PMID: 11559210.
|